Inflammation

, Volume 13, Issue 2, pp 175–184 | Cite as

Inhibition of human platelet aggregation and secretion by ant venom and a compound isolated from venom

  • W. F. Hink
  • K. J. Romstedt
  • J. W. Burke
  • R. W. Doskotch
  • D. R. Feller
Original Articles Cathepsin G Degrades Denatured Collagen

Abstract

Venom from the tropical ant,Pseudomyrmex. triplarinus, has activity against rheumatoid arthritis. Since platelets are involved in inflammatory responses, they were employed to study the effects of venom on prostaglandin-dependent human platelet aggregation and secretion. The assay is very sensitive and uses microliter volumes, which makes it useful as a screen during isolation and characterization of venom components. Whole venom inhibited arachidonic acid- and U46619-induced platelet aggregation with IC50s of 45 and 39 μg/ml, respectively. This suggested that venom prevented the action of prostaglandins. Pure venom was fractionated by gel filtration and at least three materials with antiplatelet activity were detected. The smallest component (factor F) was most active and was purified by additional molecular filtration and characterized by UV absorbance, thin-layer chromatography, nuclear magnetic resonance spectra, and activity to platelets. Factor F was identified as adenosine, which is known to stimulate platelet adenylate cyclase and has not been previously reported to be a component of insect venom.

Keywords

Rheumatoid Arthritis Nuclear Magnetic Resonance Prostaglandin Arachidonic Acid Platelet Aggregation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Altman, R. D., D. R. Schultz, B. Collins-Yudiskas, J. Aldrich, P. I. Arnold, andH. E. Brown. 1984. The effects of a partially purified fraction of an ant venom in rheumatoid arthritis.Arthritis Rheum. 27:277–284.Google Scholar
  2. 2.
    Winter, C. A., E. A. Risley, andG. W. Nuss. 1962. Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs.Proc. Soc. Exp. Biol. Med. 111:544–547.Google Scholar
  3. 3.
    Hink, W. F., andJ. J. Butz. 1985. Primary culture of ant venom gland cells.In Vitro Cell. Dev. Biol. 21:333–339.Google Scholar
  4. 4.
    Schultz, D. R., andP. I. Arnold. 1984. Invmunochemical and clinical studies of venom from the antPseudomyrmex, sp.In Handbook of Natural Toxins, Vol. 2, Insect Poisons, Aller-gens, and Other Invertebrate Venoms. A. T. Tu, editor. Marcel Dekker, New York. 243–290.Google Scholar
  5. 5.
    Philp, R. B. 1981. Methods of Testing Proposed Antithrombotic Drugs. CRC Press, Boca Raton, Florida. 278 pp.Google Scholar
  6. 6.
    Flower, R. J., S. Moncada, andJ. R. Vane. 1985. Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout.In The Pharmacological Basis of Therapeutics. A. G. Gilman, L. S. Goodman, T. S. Rall, and F. Murad, editors. Macmillan, New York. 674–715.Google Scholar
  7. 7.
    Detwiler, T. C., andE. M. Huang. 1986. Interactions of platelet activating pathways: Interrelationships of aggregation and secretion.In Platelet Responses and Metabolism, Vol. I. H. Holmsen, editor. CRC Press, Boca Raton, Florida. 235–249.Google Scholar
  8. 8.
    Mayo, J. R., S. S. Navran, Huzoor Akbar, D. D. Miller, andD. R. Feller. 1981. Stereo-dependent inhibition of human platelet function by the optical isomers of trimetoquinol.Biochem. Pharmacol. 30:2237–2241.Google Scholar
  9. 9.
    Born, G. V. R. 1962. Aggregation of blood platelets by adenosine diphosphate and its reversal.Nature 194:927–929.Google Scholar
  10. 10.
    Huzoor-Akbar, K. Romstedt, andB. Manhire. 1983. Computerized aggregation instruments: A highly efficient and versatile system for acquisition, quantitation, presentation and management of platelet aggregation data.Thromb. Res. 32:335–341.Google Scholar
  11. 11.
    Ahn, C.-H., A. Hamada, D. D. Miller, andD. R. Feller. 1986. Alpha-adrenoceptor mediated actions of optical isomers and desoxy analogs of catecholimidazoline and norepinephrine in human platelts in vitro.Biochem. Pharmacol. 35:4095–4102.Google Scholar
  12. 12.
    Hamberg, M., J. Svensson, T. Wakabayashi, andB. Samuelsson. 1974. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation.Proc. Natl. Acad. Sci. U.S.A. 71:345–349.Google Scholar
  13. 13.
    Hamberg, M., J. Svensson, andB. Samuelsson. 1975. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides.Proc. Natl. Acad. Sci. U.S.A. 72:2994–2998.Google Scholar
  14. 14.
    Samuelsson, B. 1977. The role of prostaglandin endoperoxides and thromboxanes in human platelets.In Prostaglandins in Hematology, M. J. Silver, J. B. Smith and J. J. Kocsis, editors. Spectrum Publications, New York. 1–10.Google Scholar
  15. 15.
    Halushka, P. V., D. E. Mais, andD. L. Saussy, Jr. 1987. Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors.Fed. Proc. 46:149–153.Google Scholar
  16. 16.
    Coleman, R. A., I. Kennedy, G. P. Levy, andP. Lumley. 1981. Comparison of actions of U46619, a prostaglandin H2 analog, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations.Br. J. Pharmacol. 73:773–778.Google Scholar
  17. 17.
    Bock, R. M., S. Ling, S. A. Morell, andS. H. Lipton. 1956. Ultraviolet absorption spectra of adenosine-5-triphosphate and related 5-ribonucleotides.Arch. Biochem. Biophys. 32:253–264.Google Scholar
  18. 18.
    Clayton, S., G. V. R. Born, andM. J. Cross. 1963. Inhibition of the aggregation of blood platelets by nucleosides.Nature 200:138–139.Google Scholar
  19. 19.
    Cross, M. J., G. V. R. Born, andS. Clayton. 1964. The aggregation of platelets by adenosine diphosphate.Thromb. Diath. Haemorrh. 11:301–302.Google Scholar
  20. 20.
    Born, G. V. R., R. J. Haslam, andM. Goldman. 1965. Comparative effectiveness of adenosine analogues as inhibitors of blood-platelet aggregation and as vasodilators in man.Nature 205:678–680.Google Scholar
  21. 21.
    Regoli, D., andV. Clark. 1963. Prevention by adenosine of the effect of adenosine diphosphate on the concentration of circulating platelets.Nature 200:546–548.Google Scholar
  22. 22.
    Haslam, R. J., andG. M. Rosson. 1975. Effects of adenosine on levels of adenosine cyclic 3,5-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation.Mol. Pharmacol. 11:528–544.Google Scholar
  23. 23.
    Macfarlane, D. E.. 1987. Agonists and receptors: Adenosine diphosphate.In Platelet Responses and Metabolism, Vol. II. H. Holmsen, editor. CRC Press, Boca Raton, Florida. 19–36.Google Scholar
  24. 24.
    Bonne, C., B. Martic, andF. Regnault. 1980. The cyclic AMP-lowering effect of the stable endoperoxide analog U46619 in human platelets.Thromb. Res. 20:701–704.Google Scholar
  25. 25.
    Hirschhorn, R., F. Martiniuk, andF. S. Rosen. 1978. Adenosine deaminase activity in normal tissues and tissues from a child with severe combined immunodeficiency and adenosine deaminase deficiency.Clin. Immunol. Immunopathol. 9:287–292.Google Scholar

Copyright information

© Plenum Publishing Corporation 1989

Authors and Affiliations

  • W. F. Hink
    • 1
  • K. J. Romstedt
    • 2
  • J. W. Burke
    • 2
  • R. W. Doskotch
    • 2
  • D. R. Feller
    • 2
  1. 1.Department of EntomologyOhio State UniversityColumbus
  2. 2.College of PharmacyOhio State UniversityColumbus

Personalised recommendations